A Texas-based company that is developing treatments for cancer has raised its stake in AdnaGen AG of Germany to 85% from 51%. The company, Oncovista of San Antonio, said AdnaGen’s technology for detecting circulating tumour cells (CTCs) will improve its ability to prescreen patients for clinical trials.
